Abstract: A method and apparatus for detecting an isotope. Embodiments can detect radioactive isotopes. Embodiments can utilize a detector that incorporates at least two sub-detectors. Each sub-detector can receive energy from an isotope and create a signal corresponding to the received energy. Each sub-detector can incorporate a detector element, such as a detector element incorporating one or more diodes, a detector element incorporating a crystal, a detector element incorporating a solid-state device, or a detector element incorporating a scintillator. The sub-detectors can be configured such that for each isotope to be detected at least two of the sub-detectors produce different output signals, or readings. In an embodiment, each sub-detector is configured such that when there are at least two sub-detectors exposed to the isotope each of the corresponding readings from the sub-detectors is different from each of the other readings.

Abstract: A method and apparatus for detecting an isotope. embodiments can detect radioactive isotopes. Embodiments can utilize a detector that incorporates at least two sub-detectors. Each sub-detector can receive energy from an isotope and create a signal corresponding to the received energy. Each sub-detector can incorporate a detector element, such as a detector element incorporating one or more diodes, a detector element incorporating a crystal, a detector element incorporating a solid-state device, or a detector element incorporating a scintillator. The sub-detectors can be configured such that for each isotope to be detected at least two of the sub-detectors produce different output signals, or readings. In an embodiment, each sub-detector is configured such that when there are at least two sub-detectors exposed to the isotope each of the corresponding readings from the sub-detectors are different from each of the other readings.

Abstract: Many GTPases such as Ras, Ral and Rho require post-translational farnestylation or geranylgeranylation for mediating malignant transformation. Dual farnesyltransferase (FT) (FTI) and geranylgeranyltransferase-I (GGT-1) inhibitors (GGTI) were developed as anticancer agents from based on an ethylenediamine scaffold. On the basis of a 4-fold substituted ethylenediamine scaffold, the inhibitors are structurally simple and readily derivatized, facilitating extensive structure-activity relationship studies. The most potent inhibitor is compound exhibited an in vitro hFTase IC50 value of 25 nM and a whole cell H-Ras processing IC50 value of 90 nM. Several of the inhibitors proved highly selective for hFTase over the related prenyltransferase enzyme geranylgeranyltransferase-I (GGTase-I).